Latest Conference Articles

February 8th 2020, 8:34pm

PER® Winter Lung Cancer Conference

Rogerio C. Lilenbaum, MD, discusses using PD-L1 as a predictive biomarker for immunotherapy and the search for additional biomarkers in lung cancer.

February 8th 2020, 7:51pm

PER® Winter Lung Cancer Conference

Benjamin P. Levy, MD, discusses emerging oncogenic markers in lung cancer and what impact they are poised to make on the paradigm.

February 8th 2020, 3:34am

SGO Winter Meeting

In ovarian cancer, disease that returns within 6 months of treatment following platinum-based therapy is defined as platinum-sensitive.

February 8th 2020, 2:57am

SGO Winter Meeting

Researchers and practicing physicians have done as much as possible with chemotherapy as a systemic treatment for endometrial cancers, and other modalities—alone and in combination—are likely to become standard of care in the coming years, Shannon N. Westin, MD, MPH, said during a presentation at the 2020 SGO Winter Meeting.

February 7th 2020, 3:28am

SGO Winter Meeting

Maintenance treatment with PARP inhibitors should be the standard of care in the frontline setting for patients with ovarian cancer, Kathleen M. Moore, MD, said during a presentation at the 2020 Society of Gynecologic Oncology Winter Meeting.

January 28th 2020, 2:57am

Gastrointestinal Cancers Symposium (ASCO GI)

Analysis of patient-reported outcomes from the phase III IMbrave 150 study showed meaningful benefits in quality of life, functioning, and key symptoms with atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in patients with unresectable hepatocellular carcinoma.

January 27th 2020, 10:59pm

Gastrointestinal Cancers Symposium (ASCO GI)

Encorafenib plus cetuximab with or without binimetinib demonstrated longer maintenance of quality of life on patient-reported assessments over current standard of care in the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer.

January 27th 2020, 5:08am

Gastrointestinal Cancers Symposium (ASCO GI)

Augusto Villanueva, MD, an assistant professor of the Division of Liver Diseases at the Tisch Cancer Institute of Icahn School of Medicine at Mount Sinai, discusses mutations and gene signatures for patients with hepatocellular carcinoma, a topic he presented at the 2020 Gastrointestinal Cancers Symposium.

January 27th 2020, 5:01am

Gastrointestinal Cancers Symposium (ASCO GI)

Eileen M. O’Reilly, MD, discusses the randomized phase II trial of gemcitabine and cisplatin versus gemcitabine and cisplatin and veliparib in patients with pancreas adenocarcinoma harboring a known germline BRCA or PALB2 mutation, which was presented at the 2020 Gastrointestinal Cancers Symposium.

January 27th 2020, 12:47am

Gastrointestinal Cancers Symposium (ASCO GI)

Third-line treatment of patients with metastatic colorectal cancer using regorafenib plus oral fluoropyrimidine TAS-102 provides clinically meaningful disease control with toxicities consistent with the safety profiles of either agent, according to data from the phase I dose-escalation trial REMETY presented at the 2020 Gastrointestinal Cancers Symposium.

January 27th 2020, 12:08am

Gastrointestinal Cancers Symposium (ASCO GI)

Ramucirumab as second-line therapy after sorafenib induces improved overall survival compared with placebo, irrespective of Barcelona Clinic Liver Cancer stage, in patients with intermediate-stage hepatocellular carcinoma and an elevated baseline level of alpha fetoprotein.

January 26th 2020, 9:22pm

Gastrointestinal Cancers Symposium (ASCO GI)

Tanios S. Bekaii-Saab, MD, examines the effectiveness of umbrella trials and their importance in aiding precision medicine in gastrointestinal oncology.

January 26th 2020, 8:20pm

Gastrointestinal Cancers Symposium (ASCO GI)

A regimen of avelumab and cetuximab plus oxaliplatin, leucovorin, and 5-fluorouracil in patients with RAS/BRAF-wildtype metastatic colorectal cancer induced a very high response rate but did not meet its primary progression-free survival end point.

January 26th 2020, 5:26am

Gastrointestinal Cancers Symposium (ASCO GI)

Peter R. Galle, MD, discusses the patient-reported outcomes results from the Phase III IMbrave150 study, which he presented at the 2020 Gastrointestinal Cancers Symposium

January 26th 2020, 1:48am

Gastrointestinal Cancers Symposium (ASCO GI)

Zev A. Wainberg, MD discusses the efficacy findings of pembrolizumab monotherapy versus chemotherapy for patients with PD-L1–positive advanced gastric and gastroesophageal junction cancer of high combined positive score in cohort 1 of the phase II KEYNOTE-059 and in the phase III KEYNOTE-061 and KEYNOTE-062 studies.

January 25th 2020, 11:57pm

Gastrointestinal Cancers Symposium (ASCO GI)

Scott Kopetz, MD, PhD, FACP, sheds light on encorafenib triplet and doublet options for patients with BRAF V600E–mutant metastatic colorectal cancer and other novel regimens under investigation.

January 25th 2020, 11:08pm

Gastrointestinal Cancers Symposium (ASCO GI)

The triplet regimen of nivolumab (Opdivo), ipilimumab (Yervoy), and cabozantinib (Cabometyx) achieved clinically meaningful responses in patients with advanced hepatocellular carcinoma who were either sorafenib (Nexavar)-naïve, or resistant to or intolerant of sorafenib.

January 25th 2020, 9:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

The combination of gemcitabine plus cisplatin with or without veliparib is highly active in patients with pancreatic ductal adenocarcinoma and a germline BRCA/PALB2 mutation.

January 25th 2020, 8:28pm

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with unresectable hepatocellular carcinoma who were randomized to first-line lenvatinib (Lenvima), compared with sorafenib (Nexavar), and received subsequent anticancer procedures experienced prolonged overall survival.

January 25th 2020, 2:24am

Gastrointestinal Cancers Symposium (ASCO GI)

Van Morris, MD, discusses research around treatment for patients with unresectable colorectal cancer.